Reuters logo
BRIEF-Pharnext announces positive preclinical data for its PLEODRUG PXT864
March 29, 2017 / 6:24 AM / in 9 months

BRIEF-Pharnext announces positive preclinical data for its PLEODRUG PXT864

March 29 (Reuters) - Pharnext SAS:

* Announced positive preclinical data for its PLEODRUG PXT864, in development for Alzheimer’s disease (ad)

* Use of approved standards of care (SOCS) in ad, i.e. Donepezil and memantine, shows transient efficacy and is moreover associated with side effects

* Data show that efficacy of tri-therapy combination (PXT864 + donepezil or memantine) was greater than individual drugs alone Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below